Authors Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S
Pigment cell & melanoma research Nov 2010
GLI2-mediated melanoma invasion and metastasis.Authors Alexaki VI, Javelaud D, Van Kempen LC, Mohammad KS, Dennler S, Luciani F, Hoek KS, Juàrez P, Goydos JS, Fournier PJ, Sibon C, Bertolotto C, Verrecchia F, Saule S, Delmas V, Ballotti R, Larue L, Saiag P, Guise TA, Mauviel A
Journal of the National Cancer Institute Aug 2010
Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.Authors Botton T, Puissant A, Cheli Y, Tomic T, Giuliano S, Fajas L, Deckert M, Ortonne JP, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S
Cell death and differentiation Jul 2010
Functional role of MITF phosphorylation. In vivo veritas?Authors Bertolotto C, Ballotti R
Pigment cell & melanoma research Dec 2009
{alpha}MSH and Cyclic AMP elevating agents control melanosome pH through a protein kinase A-independent mechanism.Authors Cheli Y, Luciani F, Khaled M, Beuret L, Bille K, Gounon P, Ortonne JP, Bertolotto C, Ballotti R
The Journal of biological chemistry Jul 2009
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.Authors Bailet O, Fenouille N, Abbe P, Robert G, Rocchi S, Gonthier N, Denoyelle C, Ticchioni M, Ortonne JP, Ballotti R, Deckert M, Tartare-Deckert S
Cancer research Mar 2009
In vitro and in vivo anti-melanoma effects of ciglitazone.Authors Botton T, Puissant A, Bahadoran P, Annicotte JS, Fajas L, Ortonne JP, Gozzerino G, Zamoum T, Tartare-Deckert S, Bertolotto C, Ballotti R, Rocchi S
The Journal of investigative dermatology Jan 2009